CSL Limited, a global biotherapeutics leader, has announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis. Underlying profit (NPATA) was US$3.3 billion, up 14% on a constant currency basis.
The company’s Chief Executive Officer and Managing Director, Dr. Paul McKenzie, stated that CSL Behring and its life-saving plasma therapies continue to show strong demand, while CSL Seqirus demonstrated resilience with growth in a challenging environment. CSL Vifor also grew strongly, driven by the iron business and nephrology portfolio.
To drive growth, simplify, and enhance shareholder returns, CSL has announced a suite of strategic transformation initiatives. These changes will focus on three Ps: Pipeline, Productivity, and People, aiming to make the organization leaner, more efficient, and agile.
Key initiatives include:
* Reducing fixed costs and increasing pipeline productivity through R&D consolidation
* Enhancing clinical and commercial execution with a new Portfolio Development and Commercialisation (PD&C) operating model
* Streamlining corporate functions to align with demand profiles for CSL products
* Closing underperforming centres and reducing headcount by up to 15%
* Achieving annualized cost savings of $500-550 million over the next three years
Additionally, CSL has announced its intention to demerge CSL Seqirus as a substantial ASX-listed entity before the end of Financial Year 2026. This will allow autonomy for the business to set an independent strategic direction and capitalize on potential opportunities in the highly dynamic vaccines market.
The company also plans to recommence a share buyback program, starting with A$750m in Financial Year 2026, to enhance capital efficiency and improve shareholder returns. CSL’s net debt/EBITDA ratio has declined below two times, providing opportunities for investments in high-returning growth initiatives and external partnerships.
CSL expects Financial Year 2026 group revenue growth of approximately 4-5% over Financial Year 2025 at constant currency, driven by robust demand for core therapies and improving gross margins. The company’s outlook assumes no impact from pharmaceutical sector tariffs, which it believes will not affect its ability to deliver on the strategic initiatives outlined today.
Source: https://www.prnewswire.com/news-releases/csl-announces-rise-in-full-year-net-profit-302532746.html